Statin-associated muscle injury.

Eur J Prev Cardiol

Department of Preventive Cardiology, Hartford Hospital, USA

Published: September 2015

Download full-text PDF

Source
http://dx.doi.org/10.1177/2047487315586096DOI Listing

Publication Analysis

Top Keywords

statin-associated muscle
4
muscle injury
4
statin-associated
1
injury
1

Similar Publications

Modeling statin-induced myopathy with hiPSC-derived myocytes reveals that impaired proteostasis underlies the myotoxicity and is targetable for the prevention.

Am J Physiol Cell Physiol

March 2025

Laboratory of Food Biochemistry, Department of Applied Biological Chemistry, Graduate School of Life and Agricultural Sciences, The University of Tokyo, Tokyo, Japan.

Statins, HMG-CoA reductase inhibitors, have been widely prescribed to lower circulating low-density lipoprotein cholesterol levels and reduce the risk of cardiovascular disease. Although statins are well tolerated, statin-associated muscle symptoms (SAMS) are the major adverse effect and cause statin intolerance. Therefore, understanding the molecular mechanisms of SAMS and developing effective strategies for its prevention are of significant clinical importance; however, both remain unclear.

View Article and Find Full Text PDF

What is in the Myopathy Literature?

J Clin Neuromuscul Dis

March 2025

Department of Neurology, The Neuroscience Research Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.

This update begins with the incidence and features of statin-associated muscle symptoms, which may often be misattributed. Articles on potential muscle mitochondria dysfunction from statins follow, along with recommendations for possibly avoiding statins in some patients with genetic myopathies. Next, autoimmune myopathies, including immune-mediated necrotizing myopathy, myositis with antimitochondrial antibodies, and overlap myositis with lupus, as well as the role of myxovirus protein A identification in muscle specimens, are addressed.

View Article and Find Full Text PDF

Statin-Intolerant Patients Exhibit Diminished Muscle Strength Regardless of Lipid-Lowering Therapy.

J Clin Med

February 2025

Unità Clinica Operativa Clinica Medica, Department of Medical, Surgical and Health Sciences, Faculty of Medicine, University of Trieste and ASUGI, 34149 Trieste, Italy.

Statin-associated muscle symptoms (SAMS) is a frequent side effect of statin therapy, limiting its clinical use and increasing cardiovascular risk. Its relationship with muscle performance and quality is not completely understood. The aim of our study was to retrospectively assess the differences between body composition and muscle strength in patients with SAMS, compared with matched controls.

View Article and Find Full Text PDF

Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR Outcomes trial.

J Clin Lipidol

December 2024

Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland OH, USA (Drs Lincoff and Nissen).

Background: Cholesterol Lowering via bEmpedoic Acid Regimen (CLEAR) outcomes, a randomized, double-blind, placebo-controlled cardiovascular outcomes trial, and the largest prospective database of patients with statin intolerance (SI), demonstrated that bempedoic acid reduces low-density lipoprotein cholesterol and cardiovascular risk in patients at high cardiovascular risk.

Objective: Assess baseline differences in SI symptoms and whether these influenced the clinical course during CLEAR outcomes.

Methods: Symptoms and impact of SI on daily living were recorded prior to randomization.

View Article and Find Full Text PDF

Statin‑associated myasthenia gravis: a real-world retrospective and pharmacovigilance study.

Expert Opin Drug Saf

February 2025

Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Background: Myasthenia gravis (MG) is a rare but serious adverse event (AE) of statins. Yet, its pharmacovigilance and clinical features remain unknown.

Research Design And Methods: Data were extracted from the FDA Adverse Event Reporting System (FAERS) (2004 Q1-2023 Q4), and disproportionality analyses were conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!